Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population
Conditions: Prostate Cancer; Pathology Interventions: Procedure: Transperineal Prostate Biopsy Sponsors: West China Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
ERAS for Gastric Cancer Patients After NACT
Conditions: Gastric Cancer Interventions: Other: enhanced recovery after surgery; Other: conventional perioperative management Sponsors: The Affiliated Hospital of Qingdao University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
An Phase III Study, Multicenter ，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib; Drug: Tislelizumab, Cisplatin, Gemcitabine Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Babytam vs Babyexe in Post-menopausal Women at High Risk for Breast Cancer.
Conditions: Breast Cancer Interventions: Drug: Tamoxifen 10 MG; Drug: Exemestane 25 MG Sponsors: Andrea DeCensi; Dana-Farber/Brigham and Women ' s Cancer Center; Herbert Irving Comprehensive Cancer Center; Istituto Europeo di Oncologia; Breast Cancer Research Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).
Conditions: Anal Cancer Patients Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab combined with two predefined dose groups of palbociclib; Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
Conditions: Endometrial Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer
Conditions: Predictive Cancer Model; Pathologic Complete Response Interventions: Other: Medical examination Sponsors: Sixth Affiliated Hospital, Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Esophageal Self-expandable Metal Stent for Malignant Strictures: a Safety and Efficacy Study
Conditions: Oesophageal Cancer Interventions: Device: Esophageal self-expandable metal stent Sponsors: Erasmus Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: Targeted drugs; Drug: PD-1 monoclonal antibody Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Conditions: Non-Small Cell Lung Cancer; PDL1 Negative Non-Small Cell Lung Cancer (NSCLC) Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Nivolumab; Drug: Ipilimumab Sponsors: University of Alabama at Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: PD-1 monoclonal antibody; Drug: targeted drugs Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
Conditions: Carcinoma, Hepatocellular Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Conditions: Triple Negative Breast Neoplasms Interventions: Drug: Abemaciclib; Drug: Bicalutamide Sponsors: Universitaire Ziekenhuizen KU Leuven; Kom Op Tegen Kanker; Eli Lilly and Company; Teva Pharma Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
Conditions: Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive Interventions: Drug: Mirvetuximab Soravtansine; Drug: Lubricating Eye Drops; Drug: Prednisolone acetate ophthalmic suspension 1% eye drops; Drug: Brimonidine tartrate ophthalmic solution eye drops Sponsors: ImmunoGen, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
